RT Journal Article
SR Electronic
T1 Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.10.21262933
DO 10.1101/2021.09.10.21262933
A1 Sabatino, Joseph J.
A1 Mittl, Kristen
A1 Rowles, William
A1 Mcpolin, Kira
A1 Rajan, Jayant V.
A1 Zamecnik, Colin R.
A1 Dandekar, Ravi
A1 Alvarenga, Bonny D.
A1 Loudermilk, Rita P.
A1 Gerungan, Chloe
A1 Spencer, Collin M.
A1 Sagan, Sharon A.
A1 Augusto, Danillo G.
A1 Alexander, Jessa
A1 Hollenbach, Jill A.
A1 Wilson, Michael R.
A1 Zamvil, Scott S.
A1 Bove, Riley
YR 2021
UL http://medrxiv.org/content/early/2021/09/20/2021.09.10.21262933.abstract
AB Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive understanding of how MS DMTs impact SARS-CoV-2 vaccine responses is lacking. We completed a detailed analysis of SARS-CoV-2 vaccine-elicited spike antigen-specific IgG and T cell responses in a cohort of healthy controls and MS participants in six different treatment categories. Two specific DMT types, sphingosine-1-phosphate (S1P) receptor modulators and anti-CD20 monoclonal antibodies (mAb), resulted in significantly reduced spike-specific IgG responses. Longer duration of anti-CD20 mAb treatment prior to SARS-CoV-2 vaccination were associated with absent antibody responses. Except for reduced CD4+ T cell responses in S1P-treated patients, spike-specific CD4+ and CD8+ T cell reactivity remained robust across all MS treatment types. These findings have important implications for clinical practice guidelines and vaccination recommendations in MS patients and other immunosuppressed populations.Competing Interest StatementMRW has received research grant funding from Roche/Genentech and speaking honoraria from Novartis, Takeda and Genentech. SSZ has received consulting honoraria from Alexion, Biogen-Idec, EMD-Serono, Genzyme, Novartis, Roche/Genentech, and Teva Pharmaceuticals, Inc and has served on Data Safety Monitoring Boards for Lilly, BioMS, Teva and Therapeutics. RB has received research grant funding from Roche Genentech and Biogen, and consulting honoraria from Alexion, Biogen, EMD Serono, Genzyme Sanofi, Novartis, and Roche Genentech.Funding StatementThis work was supported by grants from the NIH 1K08NS107619 (JJS), R01NS092835 (SSZ), R01AI131624 (SSZ), R21NS108159 (SSZ), NMSS TA-1903-33713 (JJS), RG1701-26628 (SSZ), and the Maisin Foundation (SSZ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCSF Committee on Human Research (IRB# 21-33240)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials. Raw data are available from the authors upon request.